A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia.
Antigens, CD
/ analysis
Antigens, CD19
/ analysis
Antigens, CD20
/ analysis
Biomarkers, Tumor
/ analysis
CD5 Antigens
/ analysis
CD79 Antigens
/ analysis
Diagnosis, Differential
Flow Cytometry
/ methods
Glycoproteins
/ analysis
Humans
Immunophenotyping
Leukemia, Lymphocytic, Chronic, B-Cell
/ diagnosis
Leukosialin
/ analysis
Logistic Models
Lymphoma, B-Cell
/ diagnosis
ROC Curve
Receptors, Antigen, B-Cell
/ analysis
Receptors, IgE
/ analysis
Sensitivity and Specificity
atypical
chronic lymphocytic leukemia
flow cytometry
immunophenotype
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
20
04
2021
received:
19
11
2020
accepted:
29
04
2021
pubmed:
2
6
2021
medline:
1
1
2022
entrez:
1
6
2021
Statut:
ppublish
Résumé
Moreau score has been used to differentiate chronic lymphocytic leukemia (CLL) from other mature B-cell neoplasms. However, it showed limitations in Asian patients. Therefore, we conducted a new score system replacing CD5 and CD23 with CD43 and CD180 to evaluate its diagnostic value of CLL. 237 untreated samples diagnosed with mature B-cell neoplasms were collected and were randomly divided into an exploratory and a validation cohort by a 2:1 ratio. The expression of CD5, CD19, CD20, CD23, CD43, CD79b, CD180, CD200, FMC7, and surface immunoglobulin (SmIg) were analyzed among all the samples. A proposed score was developed based on the logistic regression model. The sensitivity and specificity of the proposed score were calculated by ROC curves. CD43/CD180, CD200, FMC7, and CD79b were included in our new CLL score, which showed a sensitivity of 91.8% and a specificity of 83.1%. These results were confirmed in a validation cohort with a sensitivity of 90.5% (p = 0.808) and a specificity of 79.5% (p = 0.639). In CD5 negative or CD23 negative CLL group, the new CLL score displayed improved sensitivity of 79.4% compared to Moreau score and CLLflow score (41.2% and 47.1%, respectively). In atypical CLL group, the new CLL score showed improved sensitivity of 84.2% compared to Moreau score and CLLflow score (61.4% and 64.9%, respectively). This proposed atypical CLL score helped to offer an accurate differentiation of CLL from non-CLL together with morphological and molecular methods, particularly in Chinese patients with atypical immunophenotype.
Identifiants
pubmed: 34061467
doi: 10.1002/cam4.3983
pmc: PMC8267114
doi:
Substances chimiques
Antigens, CD
0
Antigens, CD19
0
Antigens, CD20
0
Biomarkers, Tumor
0
CD180 protein, human
0
CD19 molecule, human
0
CD5 Antigens
0
CD79 Antigens
0
CD79B protein, human
0
Glycoproteins
0
Leukosialin
0
MS4A1 protein, human
0
Receptors, Antigen, B-Cell
0
Receptors, IgE
0
SPN protein, human
0
antigens, CD200
UQ4V77A8VA
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4387-4396Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Med Sci Monit. 2017 May 05;23:2137-2142
pubmed: 28473690
Am J Clin Pathol. 2001 Dec;116(6):893-7
pubmed: 11764079
Cytometry B Clin Cytom. 2016 Sep;90(5):462-6
pubmed: 26384474
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Nat Immunol. 2005 Jun;6(6):571-8
pubmed: 15852007
Blood Rev. 2015 May;29(3):205-13
pubmed: 25541495
Blood. 2008 Jun 15;111(12):5446-56
pubmed: 18216293
Int J Lab Hematol. 2018 Oct;40(5):533-539
pubmed: 29806244
Cytometry B Clin Cytom. 2018 Jan;94(1):121-128
pubmed: 29024461
Hematology Am Soc Hematol Educ Program. 2009;:523-31
pubmed: 20008237
Br J Haematol. 2017 Nov;179(3):480-487
pubmed: 28832948
Am J Clin Pathol. 1997 Oct;108(4):378-82
pubmed: 9322589
Am J Hematol. 2019 Nov;94(11):1266-1287
pubmed: 31364186
Clin Lab. 2019 Nov 1;65(11):
pubmed: 31710447
Cytometry B Clin Cytom. 2018 Jan;94(1):82-93
pubmed: 28187514
Cytometry B Clin Cytom. 2016 Sep;90(5):433-9
pubmed: 26482097
N Engl J Med. 2009 Feb 12;360(7):659-67
pubmed: 19213679
Br J Haematol. 2014 Feb;164(4):536-45
pubmed: 24245986
Am J Clin Pathol. 2008 Aug;130(2):166-77
pubmed: 18628084
Leukemia. 2007 May;21(5):956-64
pubmed: 17361231
Leukemia. 1994 Oct;8(10):1640-5
pubmed: 7523797
Cytometry B Clin Cytom. 2018 Jan;94(1):136-142
pubmed: 28073173
Arch Pathol Lab Med. 2013 Nov;137(11):1610-8
pubmed: 24168498
Methods Mol Biol. 2019;2032:311-321
pubmed: 31522426
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
J Clin Oncol. 2008 Mar 10;26(8):1364-70
pubmed: 18323559
J Investig Med. 2012 Jan;60(1):56-61
pubmed: 22064604
Cytometry B Clin Cytom. 2020 Nov;98(6):476-482
pubmed: 32716606
Clin Lab. 2017 Oct 1;63(10):1621-1626
pubmed: 29035453
Br J Haematol. 2011 May;153(4):486-98
pubmed: 21443749
Hematol Oncol. 2008 Sep;26(3):167-70
pubmed: 18381689
Turk J Haematol. 2018 May 25;35(2):94-98
pubmed: 28713070
Cytometry B Clin Cytom. 2019 Jan;96(1):20-29
pubmed: 30549186
Blood. 1995 Nov 15;86(10):3883-90
pubmed: 7579357
Leukemia. 2013 Aug;27(8):1748-50
pubmed: 23302770
Int J Hematol. 2013 Mar;97(3):403-8
pubmed: 23400412
Hum Pathol. 2015 Apr;46(4):593-9
pubmed: 25682152
Exp Oncol. 2020 Mar;42(1):16-24
pubmed: 32231196
Leuk Lymphoma. 2010 Dec;51(12):2230-9
pubmed: 21067444